Official Title
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
Brief Summary

This is a national multicenter, prospective, observational study. It is planned to enroll1215 patients with newly diagnosed essential hypertension in 80 centers, and divide theminto 3 groups according to different treatment plans given by doctors: AZL-M monotherapygroup, CCB monotherapy group (amlodipine besylate tablets or nifedipinecontrolled-release tablets) and AZL-M+CCB (amlodipine besylate tablets or nifedipinecontrolled-release tablets) combined treatment group. Subjects were visited 4 times atbaseline, 1 month, 3 months, and 6 months, and the following key indicators of subjectswere measured according to the doctor's decision, and the measurement results werecollected

Detailed Description

Not Provided

Recruiting
Essential Hypertension

Drug: Azilsartan Medoxomil Potassium Tablet

Azilsartan Medoxomil Potassium Tablet,80mg,qd,lasts six month

Drug: Nifedipine Sustained -release Tablets

Nifedipine Sustained -release Tablets,qd,The maximum clinical dose,lasts six months;

Drug: Levoamlodipine Maleate Table

Levoamlodipine Maleate Table,qd,The maximum clinical dose,lasts six months;

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years old (one year old);

2. Patients diagnosed with essential hypertension;

3. Did not receive any antihypertensive drug treatment for at least 3 months before
enrollment;

4. Eligible to use 80 mg once-daily AZL-M at baseline or CCB (amlodipine besylate
tablets or nifedipine controlled-release tablets) or CCB (besylate Amlodipine
tablets or nifedipine controlled-release tablets) + AZL-M 80 mg once-daily
combination therapy; Volunteer to participate in this study, understand and sign the
written informed consent.

Exclusion Criteria:

1. Used antihypertensive drugs for indications other than hypertension within 3 months
before enrollment;

2. Has a history of alcoholism, drug abuse or illegal drug use;

3. Pregnant, breastfeeding women, and those who plan to become pregnant in the near
future;

4. Life expectancy is less than one year; Participating in other clinical trials.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Locations

Junbo Ge
Shanghai, Shanghai, China

Investigator: Junbo Ge

Contacts

Jun Bo Ge, academician
+86 13901977506
ge.junbo@zs-hospital.sh.cn

Not Provided

Hasten Biopharmaceutical Co., Ltd.
NCT Number
Keywords
essential hypertension
MeSH Terms
Hypertension
Essential Hypertension
Nifedipine
Azilsartan medoxomil